<!DOCTYPE html>
<html>
    <head> 

    <meta name="viewport" content="width=device-width">
        <meta http-equiv="Content-Type" content="text/html; charset=UTF-8">
      <meta content='width=device-width; initial-scale=1.0; maximum-scale=1.5; user-scalable=1;' name='viewport' /> 
	  <script src="jquery-1.9.1.min.js"></script>
            
           
            <link rel="stylesheet" type="text/css" href="interactives.css">

 

</head>
<body>
    <img width="100%" src="interactive_0000590.png">
						   <!-- ALGORITHM_FOR_ALOCAOREGIONAL_LYMPH_(NSCLC) -->
        <div style="float:right; width:70px; padding:0px 0px 3px 0px;">
                <button id="pdf_button" class="flip-pdf-button"  >
                    <a href="flipView"> <img src="algo.png" class="pdf-image"></img></a>
                </button>
        </div>
		<br/><br/><br/><br/>
    <div id="reference">
	<div class="info_text_box_abb">NA = not available.
	<!-- <div class="info_text_box_abb">
		 <p class="text-left">ACE-I = angiotensin-converting enzyme inhibitor; ARB = angiotensin receptor blocker; ARNI = angiotensin receptor neprilysin inhibitor; BNP = B-type natriuretic peptide; CRT = cardiac resynchronization therapy; HF = heart failure; HFrEF = heart failure with reduced ejection fraction; H-ISDN = hydralazine and isosorbide dinitrate; HR = heart rate; ICD = implantable cardioverter defibrillator; LBBB = left bundle branch block; LVAD = left ventricular assist device; LVEF = left ventricular ejection fraction; MR = mineralocorticoid receptor; NT-proBNP = N-terminal pro-B type natriuretic peptide; NYHA = New York Heart Association; OMT = optimal medical therapy; VF = ventricular fibrillation; VT = ventricular tachycardia.</p>  -->
		
	</div>
	<br/>
<!-- <div class="info_text_box_abb">
		<p class="text-left"><sup>a</sup>Symptomatic = NYHA Class II-IV.<br/><sup>b</sup>HFrEF = LVEF <40%.<br/><sup>c</sup>If ACE inhibitor not tolerated/contra-indicated, use ARB.<br/><sup>d</sup>If MR antagonist not tolerated/contra-indicated, use ARB.<br/><sup>e</sup>With a hospital admission for HF within the last 6 months or with elevated natriuretic peptides (BNP >250 pg/ml or NTproBNP >500 pg/ml in men and 750 pg/ml in women).<br/><sup>f</sup>With an elevated plasma natriuretic peptide level (BNP ≥150 pg/mL or plasma NT-proBNP ≥600 pg/mL, or if HF hospitalization within recent 12 months plasma BNP ≥100 pg/mL or plasma NT-proBNP ≥400 pg/mL).<br/><sup>g</sup>In doses equivalent to enalapril 10 mg b.i.d.<br/><sup>h</sup>With a hospital admission for HF within the previous year.<br/><sup>i</sup>CRT is recommended if QRS ≥130 msec and LBBB (in sinus rhythm).<br/><sup>j</sup>CRT should/may be considered if QRS ≥130 msec with non-LBBB (in a sinus rhythm) or for patients in AF provided a strategy to ensure bi-ventricular capture in place (individualized decision).<br/>For further details, see Sections 7 and 8 and corresponding web pages in the main document.<br/>*Diuretics to relieve symptoms and signs of congestion<br/>**If LVEF  35% despite OMT or a history of symptomatic VT/VF, implant ICD</p>
		
	</div> -->
	
</div> 
</body>
</html>